In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Novartis licenses rights in emerging markets to GW Pharma's Sativex

Executive Summary

Novartis Pharma AG has licensed exclusive marketing rights in Australia, New Zealand, Asia (excluding Japan, China, and Hong Kong), the Middle East (excluding Israel/Palestine, which is Neopharm Ltd.’s licensed area), and Africa to GW Pharmaceuticals PLC’s (cannabis therapeutics) Sativex (tetrahydrocannabinol/cannabidiol).

Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R&D and Marketing (Licensing)

Related Companies